Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005643 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Sarcoma of the Uterus
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005643: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00005643 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005643, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have advanced or recurrent sarcoma of the uterus.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-05 |
| Phase | Phase 2 |
What the finished NCT00005643 record still lists
NCT00005643 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00005643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005643 about?
NCT00005643 is a clinical study titled "Chemotherapy in Treating Patients With Sarcoma of the Uterus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have advanced or recurrent sarcoma of the uterus.
What is the current status of trial NCT00005643?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-05.
What interventions are being tested in trial NCT00005643?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005643?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia